Olema Pharmaceuticals (OLMA) Change in Accured Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Change in Accured Expenses data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 111.59% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $23.5 million, a 6474.3% increase from a year earlier, with the FY2025 full-year figure at $11.0 million, down 1.95% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.3 million, down from $3.6 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for OLMA reached as high as $12.7 million in Q2 2025 and fell as low as -$11.2 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of $2.2 million in 2024.
• Across the five-year window, Change in Accured Expenses surged 2481.42% in 2023 and tumbled 2684.16% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.7 million in 2022, then surged by 38.37% to $5.2 million in 2023, then slumped by 56.87% to $2.2 million in 2024, then jumped by 62.83% to $3.6 million in 2025, then slumped by 64.09% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $1.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.9 million in Q3 2025.